New Publication!

We are happy to share our new collaboration! In this new publication in Current Medical Research and Opinion, Bart Heeg collaborated to indirectly compare the efficacy of bosutinib with nilotinib and dasatinib in first-line chronic-phase chronic myeloid leukemia. Because heterogeneity in terms of patient baseline characteristics and imatinib dose escalation are difficult to adjust for in network

Lees meer

Myeloma Action Month

For the final week of #MyelomaActionMonth Ingress is proud to highlight its methodological publication on extrapolating survival data of multiple myeloma patients which was referenced in NICE DSU Technical Support Document 21! In this study, our colleagues Mahmoud Hashim and Bart Heeg collaborated to demonstrate how clinical trial data can be extrapolated using historical trial data–based a priori distributions. They presented

Lees meer

New Publication! New Systematic Review of Noninferiority Margins in Oncology

We are happy to share that our colleagues Mahmoud Hashim, Talitha Vincken, and Florint Kroi just published a new systematic review of noninferiority margins in oncology in the Journal of Comparative Effectiveness Research. Noninferiority clinical trials are designed to evaluate if the efficacy of an experimental intervention is not unacceptably worse than that of a standard of care treatment.

Lees meer

Myeloma Action Month

The next publication we want to highlight in this #myelomactionmonth is a patient preference study from our #RWE team! In this study Thomas Wilke and Sabrina Müller collaborated to investigate the preferences of patients with relapsed/refractory MM with novel proteasome inhibitor-based combination treatments using a discrete choice experiment. They found that patients with RRMM prefer treatments with an all-oral application, a

Lees meer

Myeloma Action Month

Our colleagues Margarita Kulakova, Bart Heeg and Mahmoud Hashim collaborated on a large meta-review of the role of MRD negativity in long term survival outcomes in patients with multiple myeloma. The strong prognostic value of MRD negativity and its association with favorble outcomes sets the stage to adopt MRD as a treatment endpoint. If you would like to know more

Lees meer

Happy International Women’s Day!

At Ingress-Health we #choosetochallenge industry norms every day. Happy International Women’s day to everyone! #Choosetochallenge #IWD2021 #womenatwork #womeninscience #ingressteam

Lees meer

March Myeloma Action

This month is Multiple Myeloma Action Month! At Ingress-health we have an extensive experience in multiple myeloma, publishing manuscripts in many areas of the disease, including: the value of MRD-, comparative effectiveness of new agents, patient preferences, the impact of treatments on high risk cytogenetics and methodology to better predict survival of patients with multiple myeloma. As

Lees meer

Claims data study

We are happy to share that our colleagues Marco Ghiani, Sabrina Müller and Thomas Wilke from the RWE-team just published a new claims data study in the International Journal of Stroke. The study shows that patients hospitalized with a stroke at the weekend had higher mortality and healthcare costs compared to regular working days. Thanks

Lees meer

Welcome to Ingress Friso!

We are happy to announce that Friso Reitsma has joined our Rotterdam office as a Consultant! Friso graduated with a master’s degree in Health Economics, Policy and Law at the Erasmus University in Rotterdam and holds two bachelor’s degrees from the University of Groningen – one in Psychology and one in Business Administration. He has

Lees meer

FD Gazelle 2020

We did it again! This year, we again ranked amongst the fastest growing companies in the Netherlands. We are proud that we have continued our growth and we want to thank our clients and our amazing team for making this wonderful achievement possible #proud #FDGazelle2020 #Ingresssteam #HEOR

Lees meer